Market Overview

UPDATE: Jefferies Downgrades Johnson & Johnson to Hold, Lowers PT

Share:
Related JNJ
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Eli Lilly's Taltz Gets Approval For Label Expansion in US
Positive Market In 2017 - Cramer's Mad Money (12/11/17) (Seeking Alpha)

In a report published Monday, Jefferies downgraded Johnson & Johnson (NYSE: JNJ) from Buy to Hold, and reduced price target form $78 to $75.

Jefferies noted, "Whilst we still see the potential for J&J shares to outperform through more aggressive capital allocation, we have little evidence to formally model this at present. We had hoped that the MD&D day, which has now been postponed due to hurricane Sandy, could have provided a platform to raise expectations either around capital allocation or balance sheet leverage. We will have to wait for now and we prefer to do this from the sidelines as our current valuation provides limited upside against a worsening environment for reimbursement in both the US and Europe. Our target price of $75 is calculated by placing our 2014E EPS estimate on a 10%-20% premium to the U.S. market PE."

Johnson & Johnson closed at $69.87 on Friday.

Latest Ratings for JNJ

DateFirmActionFromTo
Oct 2017CitigroupMaintainsBuy
Oct 2017Credit SuisseMaintainsOutperform
Oct 2017BarclaysMaintainsEqual-Weight

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!

Partner Center